Inozyme Pharma Inc Cash Flow-to-Debt Ratio
Inozyme Pharma Inc cash flow-to-debt ratio. Inozyme Pharma Inc (INZY) has a Cash Flow-to-Debt Ratio of -0.46x as of March 2025, meaning its operating cash flow of $-29.15 Million could theoretically repay 0% of its total liabilities ($63.37 Million) in one year. See how financially flexible is Inozyme Pharma Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Inozyme Pharma Inc (2018–2024)
Cash flow-to-debt ratio of Inozyme Pharma Inc from 2018 to 2024. Historical debt coverage capacity for Inozyme Pharma Inc across 7 annual periods. Also explore how fast is Inozyme Pharma Inc growing its equity to track the company's year-over-year net asset growth rate.
Inozyme Pharma Inc Cash Flow-to-Debt Ratio by Year (2018–2024)
Inozyme Pharma Inc cash flow-to-debt ratio by year from 2018 to 2024. Year-by-year debt coverage analysis for Inozyme Pharma Inc. For the full cash flow conversion analysis, see Inozyme Pharma Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.41x | $-91.91 Million | $65.36 Million | ▼ -20.1% |
| 2023 | -1.17x | $-70.67 Million | $60.37 Million | ▲ +57.8% |
| 2022 | -2.78x | $-57.76 Million | $20.80 Million | ▲ +17.7% |
| 2021 | -3.37x | $-48.15 Million | $14.27 Million | ▼ -5.6% |
| 2020 | -3.19x | $-35.97 Million | $11.26 Million | ▼ -1278.5% |
| 2019 | -0.23x | $-18.81 Million | $81.16 Million | ▼ -41.0% |
| 2018 | -0.16x | $-9.44 Million | $57.42 Million | — |